11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Autoregulation of von Willebrand factor function by a disulfide bond switch

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We demonstrate mechanochemical regulation of platelet adhesion to von Willebrand factor in thrombosis and hemostasis.

          Abstract

          Force-dependent binding of platelet glycoprotein Ib (GPIb) receptors to plasma von Willebrand factor (VWF) plays a key role in hemostasis and thrombosis. Previous studies have suggested that VWF activation requires force-induced exposure of the GPIb binding site in the A1 domain that is autoinhibited by the neighboring A2 domain. However, the biochemical basis of this “mechanopresentation” remains elusive. From a combination of protein chemical, biophysical, and functional studies, we find that the autoinhibition is controlled by the redox state of an unusual disulfide bond near the carboxyl terminus of the A2 domain that links adjacent cysteine residues to form an eight-membered ring. Only when the bond is cleaved does the A2 domain bind to the A1 domain and block platelet GPIb binding. Molecular dynamics simulations indicate that cleavage of the disulfide bond modifies the structure and molecular stresses of the A2 domain in a long-range allosteric manner, which provides a structural explanation for redox control of the autoinhibition. Significantly, the A2 disulfide bond is cleaved in ~75% of VWF subunits in healthy human donor plasma but in just ~25% of plasma VWF subunits from heart failure patients who have received extracorporeal membrane oxygenation support. This suggests that the majority of plasma VWF binding sites for platelet GPIb are autoinhibited in healthy donors but are mostly available in heart failure patients. These findings demonstrate that a disulfide bond switch regulates mechanopresentation of VWF.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Biochemistry and genetics of von Willebrand factor.

          J Sadler (1998)
          Von Willebrand factor (VWF) is a blood glycoprotein that is required for normal hemostasis, and deficiency of VWF, or von Willebrand disease (VWD), is the most common inherited bleeding disorder. VWF mediates the adhesion of platelets to sites of vascular damage by binding to specific platelet membrane glycoproteins and to constituents of exposed connective tissue. These activities appear to be regulated by allosteric mechanisms and possibly by hydrodynamic shear forces. VWF also is a carrier protein for blood clotting factor VIII, and this interaction is required for normal factor VIII survival in the circulation. VWF is assembled from identical approximately 250 kDa subunits into disulfide-linked multimers that may be > 20,000 kDa. Mutations in VWD can disrupt this complex biosynthetic process at several steps to impair the assembly, intracellular targeting, or secretion of VWF multimers. Other VWD mutations impair the survival of VWF in plasma or the function of specific ligand binding sites. This growing body of information about VWF synthesis, structure, and function has allowed the reclassification of VWD based upon distinct pathophysiologic mechanisms that appear to correlate with clinical symptoms and the response to therapy.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Platelets and shear stress.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

              Proteolytic cleavage of von Willebrand factor (vWF) takes place in the circulating blood of healthy subjects and is increased in some patients with von Willebrand disease type 2A. The hemostatically active large vWF multimers are degraded to smaller less active forms. It has been suggested that the polypeptide subunit of vWF is cleaved at the peptide bond 842Tyr-843Met. We purified (approximately 10,000-fold) from human plasma a vWF-degrading protease, using chelating Sepharose, hydrophobic interaction chromatography, and gel filtration. The enzyme was found to be virtually absent in the platelet lysates obtained by repeated freezing and thawing. The proteolytic activity was associated with a high molecular weight protein (approximately 300 kD) as judged by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. vWF was resistant against the protease in a neutral buffer at physiological ionic strength but became degraded at low salt concentration or in the presence of 1 mol/L urea. No degradation of human fibrinogen, bovine serum albumin, of calf skin collagen by the purified protease was noted under the same experimental conditions. Proteolytic activity showed a pH optimum at 8 to 9 and was strongly inhibited by chelating agents, whereas only slow inhibition was observed with N-ethylmaleimide. There was no inhibition by iodoacetamide, leupeptin, or serine protease inhibitors. The best peptidyl diazomethyl ketone inhibitor was Z-Phe-Phe-CHN2. Activation by divalent metal ions was found to increase in the following order: Zn2+ approximately Cu2+ approximately CD2+ approximately Ni2+ approximately Co2+
                Bookmark

                Author and article information

                Journal
                Sci Adv
                Sci Adv
                SciAdv
                advances
                Science Advances
                American Association for the Advancement of Science
                2375-2548
                February 2018
                28 February 2018
                : 4
                : 2
                : eaaq1477
                Affiliations
                [1 ]The Centenary Institute, Newtown, New South Wales, Australia.
                [2 ]St George Clinical School, Kogarah, New South Wales, Australia.
                [3 ]Heart Research Institute and Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
                [4 ]Heidelberg Institute for Theoretical Studies, Schloß-Wolfsbrunnenweg 35, Heidelberg, Germany.
                [5 ]Interdisciplinary Center for Scientific Computing, Heidelberg University, Heidelberg, Germany.
                [6 ]Department of Cancer Biology and Therapeutics, John Curtin School of Medicine, Australian National University, Canberra, Australia.
                [7 ]Haematology Unit, Alfred Hospital, Melbourne, Victoria, Australia.
                [8 ]Intensive Care Unit, Alfred Hospital, Melbourne, Victoria, Australia.
                [9 ]Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
                [10 ]Fritz Haber Institute, Faradayweg 4-6, Berlin-Dahlem, Germany.
                [11 ]Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
                [12 ]National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
                Author notes
                [*]

                Present address: Max Planck Tandem Group in Computational Biophysics, University of Los Andes, Bogotá, Colombia.

                [†]

                Present address: Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

                []Corresponding author. Email: phil.hogg@ 123456sydney.edu.au
                Author information
                http://orcid.org/0000-0001-5205-4682
                http://orcid.org/0000-0003-4584-2044
                http://orcid.org/0000-0002-7591-0864
                http://orcid.org/0000-0002-0503-7166
                http://orcid.org/0000-0001-9453-9688
                http://orcid.org/0000-0002-2752-1522
                http://orcid.org/0000-0002-3750-0661
                http://orcid.org/0000-0003-3663-3224
                http://orcid.org/0000-0001-9963-1424
                http://orcid.org/0000-0003-2637-6009
                http://orcid.org/0000-0002-4750-1991
                http://orcid.org/0000-0001-6486-2863
                Article
                aaq1477
                10.1126/sciadv.aaq1477
                5834005
                29507883
                0e57cc3d-f869-4742-9416-d0956595914c
                Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

                This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

                History
                : 06 October 2017
                : 30 January 2018
                Categories
                Research Article
                Research Articles
                SciAdv r-articles
                Biochemistry
                Biophysics
                Biochemistry
                Custom metadata
                Roemilyn Cabal

                Comments

                Comment on this article